MCID: EPN002
MIFTS: 57

Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ependymoma

MalaCards integrated aliases for Ependymoma:

Name: Ependymoma 54 60 30 56 6 17 74
Tanycytic Ependymoma 54 74
Papillary Ependymoma 54 74
Cellular Ependymoma 54 74
Classic Ependymoma 54 60
Who Grade Ii Ependymal Neoplasm 54
Epithelial Ependymoma 54
Clear Cell Ependymoma 54
Ependymoma, Familial 54

Characteristics:

Orphanet epidemiological data:

60
ependymoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: All ages;

Classifications:



External Ids:

ICD10 via Orphanet 35 D43.2
UMLS via Orphanet 75 C0014474
Orphanet 60 ORPHA251636

Summaries for Ependymoma

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 251636Disease definitionEpendymoma is the most frequent intramedullary tumor in adults (but accounts for only 10-12% of pediatric central nervous system tumors), and can be benign or anaplastic. Ependymoma arise from the ependymal cells of the cerebral ventricles, corticle rests and central canal of the spinal cord, and manifest with variable symptoms such headache, vomiting, seizures, focal neurological signs and loss of vision and can cause obstructive hydrocephalus in some cases.Visit the Orphanet disease page for more resources.

MalaCards based summary : Ependymoma, also known as tanycytic ependymoma, is related to malignant ependymoma and myxopapillary ependymoma. An important gene associated with Ependymoma is MEN1 (Menin 1), and among its related pathways/superpathways are DNA Damage and Neuroscience. The drugs Vincristine and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 An ependymoma is a tumor that arises from the ependyma, a tissue of the central nervous system. Usually,... more...

Related Diseases for Ependymoma

Diseases in the Ependymoma family:

Benign Ependymoma Malignant Ependymoma
Malignant Adult Ependymoma

Diseases related to Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 359)
# Related Disease Score Top Affiliating Genes
1 malignant ependymoma 33.9 GFAP NF2 RELA
2 myxopapillary ependymoma 33.9 GFAP MUC1 NCAM1 S100B VIM
3 cellular ependymoma 33.8 GFAP RELA SYP
4 anaplastic ependymoma 33.8 GFAP MUC1 NF2 RELA S100B SYP
5 brain ependymoma 33.7 EGFR MKI67
6 benign ependymoma 33.6 ENO2 GFAP NF2 SYP
7 tanycytic ependymoma 33.3 GFAP MEN1 NES NF2 SYP
8 clear cell ependymoma 33.2 ENO2 GFAP MUC1 SYP VIM
9 papillary ependymoma 32.3 ENO2 GFAP NES S100B SYP TTR
10 subependymal glioma 31.7 ENO2 GFAP SYP
11 subependymoma 31.6 ENO2 GFAP NCAM1 NES SYP
12 secretory meningioma 30.4 MUC1 VIM
13 angiocentric glioma 30.3 GFAP S100B SYP VIM
14 ependymoblastoma 30.3 GFAP NES VIM
15 chordoma 30.1 EGFR GFAP MUC1 S100B VIM
16 hemangioblastoma 30.1 ENO2 GFAP MUC1 S100B SYP
17 neurofibroma 30.0 MUC1 NF2 S100B SYP
18 medulloblastoma 30.0 EGFR ENO2 GFAP HOTAIR MGMT NCAM1
19 teratoma 29.9 ENO2 GFAP NES SYP
20 tuberous sclerosis 29.9 GFAP S100B SYP VIM
21 papilloma of choroid plexus 29.8 GFAP MUC1 S100B SYP TTR
22 chordoid meningioma 29.8 GFAP MUC1 S100B SYP VIM
23 medulloepithelioma 29.8 GFAP NES SYP VIM
24 embryonal sarcoma 29.8 MKI67 S100B VIM
25 cystic teratoma 29.7 ENO2 GFAP SYP
26 renal cell carcinoma, nonpapillary 29.7 EGFR HOTAIR MUC1 VIM
27 malignant fibroxanthoma 29.7 MKI67 MUC1 S100B VIM
28 carcinoid syndrome 29.7 ENO2 MEN1 SYP
29 neuroma 29.7 ENO2 GFAP NF2 S100B
30 pheochromocytoma 29.5 ENO2 MEN1 NCAM1 SYP
31 ganglioneuroma 29.5 ENO2 GFAP NCAM1 SYP
32 ganglioglioma 29.5 ENO2 GFAP NES S100B SYP
33 oligodendroglioma 29.4 EGFR ENO2 GFAP MGMT S100B SYP
34 central neurocytoma 29.4 ENO2 GFAP NES SYP
35 hydrocephalus 29.4 ENO2 GFAP NES SYP TTR
36 neuroendocrine tumor 29.4 ENO2 MEN1 NCAM1 SYP
37 glioblastoma multiforme 29.3 EGFR GFAP MGMT NES RB1
38 astroblastoma 29.2 ENO2 GFAP NES SYP VIM
39 atypical teratoid rhabdoid tumor 29.2 GFAP HOTAIR SYP
40 meningioma, familial 29.0 ENO2 GFAP MEN1 MKI67 NF2 SYP
41 gliosarcoma 28.8 EGFR ENO2 GFAP MGMT NES RB1
42 pediatric ependymoma 12.5
43 adult brain ependymoma 12.2
44 spinal cord ependymoma 12.2
45 pediatric supratentorial ependymoma 12.2
46 pediatric infratentorial ependymoma 12.1
47 rela fusion-positive ependymoma 12.1
48 brain stem ependymoma 12.0
49 malignant adult ependymoma 12.0
50 adult spinal cord ependymoma 12.0

Graphical network of the top 20 diseases related to Ependymoma:



Diseases related to Ependymoma

Symptoms & Phenotypes for Ependymoma

GenomeRNAi Phenotypes related to Ependymoma according to GeneCards Suite gene sharing:

27 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.91 RB1 TP73
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.91 MEN1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.91 TP73
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.91 EGFR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.91 EGFR RB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.91 MEN1 TIMP3 TP73
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.91 MEN1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.91 RB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.91 TIMP3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.91 TIMP3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.91 RB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.91 MEN1 RB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.91 EGFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.91 TP73
15 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.91 TP73
16 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.91 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.91 RB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 EGFR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.91 TIMP3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.91 EGFR MEN1 RB1 TIMP3 TP73
21 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.91 MEN1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.91 MEN1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.91 RB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.91 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.91 TIMP3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-69 9.91 TP73
27 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.91 MEN1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 EGFR TIMP3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.91 TP73
30 Decreased cell migration GR00055-A-1 9.35 EGFR MUC1 NCAM1 NF2 VIM

MGI Mouse Phenotypes related to Ependymoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 EGFR GFAP MEN1 MGMT NF2 RB1
2 nervous system MP:0003631 9.9 EGFR ENO2 GFAP MEN1 NCAM1 NF2
3 digestive/alimentary MP:0005381 9.87 EGFR GFAP MEN1 RB1 RELA TP73
4 respiratory system MP:0005388 9.61 EGFR ENO2 MGMT NF2 RB1 RELA
5 vision/eye MP:0005391 9.32 EGFR GFAP NCAM1 NF2 RB1 RELA

Drugs & Therapeutics for Ependymoma

Drugs for Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
2
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
3
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
4
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
6
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
7
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
8
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
9
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
10
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
17
Valproic Acid Approved, Investigational Phase 2, Phase 3,Phase 1 99-66-1 3121
18
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6 774
19
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
20
Dopamine Approved Phase 3,Phase 2,Early Phase 1,Not Applicable 62-31-7, 51-61-6 681
21
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
23 Trofosfamide Investigational Phase 2, Phase 3 22089-22-1
24 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
25
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
26 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Folate Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
44 Keratolytic Agents Phase 3,Phase 2,Phase 1
45 Podophyllotoxin Phase 3,Phase 2,Phase 1 518-28-5
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
47 Analgesics, Opioid Phase 3
48 Cola Phase 3,Phase 1
49 Anesthetics Phase 3,Phase 1
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 262)
# Name Status NCT ID Phase Drugs
1 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
2 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
3 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Completed NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
8 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
11 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
12 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
13 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
14 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
15 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
16 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
17 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
18 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
19 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
20 Everolimus for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
21 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
22 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
23 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
24 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
25 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
26 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
27 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
28 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
29 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
30 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
31 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
32 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Completed NCT00187226 Phase 2
33 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
34 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
35 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
36 Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors Completed NCT00006450 Phase 2 Phenylbutyrate
37 A Phase I/II Study of the Photon Radiosurgery System Completed NCT00179907 Phase 1, Phase 2
38 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
39 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
40 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
41 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
42 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
43 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
44 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
45 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
46 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
47 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
48 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
49 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
50 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy

Search NIH Clinical Center for Ependymoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Ependymoma

Genetic tests related to Ependymoma:

# Genetic test Affiliating Genes
1 Ependymoma 30

Anatomical Context for Ependymoma

MalaCards organs/tissues related to Ependymoma:

42
Brain, Spinal Cord, Bone, T Cells, Bone Marrow, Testes, Pituitary

Publications for Ependymoma

Articles related to Ependymoma:

(show top 50) (show all 1458)
# Title Authors Year
1
Destructive arthropathy of the shoulder complicating a cervical ependymoma. ( 30890366 )
2019
2
A systematic review of outcome in intramedullary ependymoma and astrocytoma. ( 30833131 )
2019
3
The value of high-dose radiotherapy in intracranial ependymoma. ( 30865382 )
2019
4
Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues. ( 30868390 )
2019
5
Spinal melanotic ependymoma: A case report and review of literature. ( 30871914 )
2019
6
Ependymoma of the spinal cord in children. A Retrospective French study. ( 30877001 )
2019
7
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. ( 30883662 )
2019
8
Quantitative Analysis of Near-Infrared Indocyanine Green Videoangiography for Predicting Functional Outcomes After Spinal Intramedullary Ependymoma Resection. ( 30888018 )
2019
9
Natural Course of Myxopapillary Ependymoma: Unusual Case Report and Review of Literature. ( 30321682 )
2019
10
Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial. ( 30460634 )
2019
11
Radiosurgery or hypofractionated stereotactic radiotherapy after craniospinal irradiation in children and adults with medulloblastoma and ependymoma. ( 30515559 )
2019
12
Individualized treatment for a case of recurrent ovarian ependymoma. ( 30588035 )
2019
13
Management of Ependymoma in Children, Adolescents and Young Adults. ( 30616927 )
2019
14
A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review. ( 30631904 )
2019
15
Challenges in the management of localized intracranial ependymoma in children: Experience from a referral oncology center in Eastern India. ( 30661422 )
2019
16
Clinical Characteristics and Prognostic Factors of Treatment in Pediatric Posterior Cranial Fossa Ependymoma. ( 30699434 )
2019
17
To Treat, or Not to Treat, That is the Question for a 13-Month-Old Girl with Cranial Ependymoma and an Unknown Spinal Mass. ( 30712706 )
2019
18
Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. ( 30768777 )
2019
19
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. ( 30811284 )
2019
20
Re-irradiation of locally recurrent pediatric intracranial ependymoma: Experience of the French society of children's cancer. ( 30825956 )
2019
21
Myxopapillary Ependymoma. ( 30844350 )
2019
22
Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. ( 30850560 )
2019
23
Outcome predictors in the management of intramedullary classic ependymoma: An integrative survival analysis. ( 29879023 )
2018
24
Keyhole Contralateral Interhemispheric Endoscopic-Assisted Resection of an Ependymoma of the Third Ventricle. ( 29351681 )
2018
25
Unique combination of myxopapillary ependymoma and conus lipoma with subcutaneous extension in an 11-month-old child. ( 29380114 )
2018
26
Treatment challenges and outcomes for pediatric intracranial ependymoma at a single institution in Iran. ( 29565756 )
2018
27
NF2 and ATRX gene copy number losses on a case of ovarian ependymoma. ( 29944970 )
2018
28
Adult Supratentorial Extraventricular Anaplastic Ependymoma: Therapeutic Approach and Clinical Review. ( 29492136 )
2018
29
Pediatric Supratentorial Ependymoma: Surgical, Clinical, and Molecular Analysis. ( 29917116 )
2018
30
Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. ( 29229328 )
2018
31
RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. ( 29063976 )
2018
32
Intramedullary ependymoma: long-term outcome after surgery. ( 29280009 )
2018
33
Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology. ( 29774098 )
2018
34
Multiple extraspinal recurrences of ependymoma 13 years after spinal cordectomy: case report. ( 29701571 )
2018
35
Extraspinal sacrococcygeal ependymoma masquerading as sacrococcygeal teratoma in the pediatric patient. ( 29138922 )
2018
36
Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma. ( 29500084 )
2018
37
Teaching Case 2-2018: Sclerosing myxopapillary ependymoma mimicking whorling-sclerosing meningioma. ( 29436365 )
2018
38
Supratentorial Pure Cortical Ependymoma: An Unusual Lesion Causing Focal Motor Aware Seizure. ( 29725181 )
2018
39
Pediatric extraspinal sacrococcygeal ependymoma (ESE): an Italian AIEOP experience of six cases and literature review. ( 29725826 )
2018
40
Gastroparesis following resection of a fourth ventricle ependymoma in a child. ( 29933085 )
2018
41
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. ( 29258295 )
2018
42
Ependymoma Superenhancer Profiling Reveals Potential Therapeutic Targets. ( 29330264 )
2018
43
Supratentorial Extraventricular Ependymoma (STEE): Retrospective analysis of 15 patients at a Single Institution. ( 29879510 )
2018
44
Surgical outcomes of spinal cord and cauda equina ependymoma: Postoperative motor status and recurrence for each WHO grade in a multicenter study. ( 29610008 )
2018
45
Identification of FDA-approved oncology drugs with selective potency in high-risk childhood ependymoma. ( 29925527 )
2018
46
Giant cell ependymoma of cervical medullary junction: a case report of a long term survivor and review of literature. ( 29772366 )
2018
47
Radiation necrosis following proton therapy successfully treated by low-dose bevacizumab in a patient with relapsed anaplastic ependymoma. ( 29667785 )
2018
48
Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma. ( 29704232 )
2018
49
Pediatric Isolated Cortical (Ectopic) Anaplastic Ependymoma. ( 29492147 )
2018
50
An Extremely Rare Case of Back and Hip Pain due to the Metastasis of Late Recurrent Myxopapillary Ependymoma to the Inguinal Lymph Node. ( 29166763 )
2018

Variations for Ependymoma

ClinVar genetic disease variations for Ependymoma:

6 (show top 50) (show all 73)
# Gene Variation Type Significance SNP ID Assembly Location
1 MSH6 NM_000179.2(MSH6): c.866_867delGCinsAA (p.Gly289Glu) indel Uncertain significance rs267608079 GRCh37 Chromosome 2, 48025988: 48025989
2 MSH6 NM_000179.2(MSH6): c.866_867delGCinsAA (p.Gly289Glu) indel Uncertain significance rs267608079 GRCh38 Chromosome 2, 47798849: 47798850
3 RET NM_020975.4(RET): c.1699G> A (p.Asp567Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs147219360 GRCh37 Chromosome 10, 43608351: 43608351
4 RET NM_020975.4(RET): c.1699G> A (p.Asp567Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs147219360 GRCh38 Chromosome 10, 43112903: 43112903
5 MEN1 NM_000244.3(MEN1): c.711dup (p.Lys238Glnfs) duplication Pathogenic rs1555165565 GRCh37 Chromosome 11, 64575111: 64575111
6 MEN1 NM_000244.3(MEN1): c.711dup (p.Lys238Glnfs) duplication Pathogenic rs1555165565 GRCh38 Chromosome 11, 64807639: 64807639
7 GON4L NM_001282856.1(GON4L): c.2455A> G (p.Asn819Asp) single nucleotide variant Uncertain significance rs1553200563 GRCh37 Chromosome 1, 155742897: 155742897
8 GON4L NM_001282856.1(GON4L): c.2455A> G (p.Asn819Asp) single nucleotide variant Uncertain significance rs1553200563 GRCh38 Chromosome 1, 155773106: 155773106
9 HDAC3 NM_003883.3(HDAC3): c.50_55+5delACTACGGTGAG deletion Uncertain significance rs1554218152 GRCh37 Chromosome 5, 141016298: 141016308
10 HDAC3 NM_003883.3(HDAC3): c.50_55+5delACTACGGTGAG deletion Uncertain significance rs1554218152 GRCh38 Chromosome 5, 141636731: 141636741
11 SETD9 NM_001323022.1(SETD9): c.329_337delACATTGCCT (p.Ile111_Tyr113del) deletion Uncertain significance rs1554039146 GRCh37 Chromosome 5, 56210766: 56210774
12 SETD9 NM_001323022.1(SETD9): c.329_337delACATTGCCT (p.Ile111_Tyr113del) deletion Uncertain significance rs1554039146 GRCh38 Chromosome 5, 56914939: 56914947
13 BANP NM_079837.2(BANP): c.575A> G (p.Asn192Ser) single nucleotide variant Uncertain significance rs1555586650 GRCh37 Chromosome 16, 88052070: 88052070
14 BANP NM_079837.2(BANP): c.575A> G (p.Asn192Ser) single nucleotide variant Uncertain significance rs1555586650 GRCh38 Chromosome 16, 88018464: 88018464
15 SUV39H1 NM_003173.3(SUV39H1): c.415C> T (p.Arg139Cys) single nucleotide variant Uncertain significance rs368779259 GRCh37 Chromosome X, 48558731: 48558731
16 SUV39H1 NM_003173.3(SUV39H1): c.415C> T (p.Arg139Cys) single nucleotide variant Uncertain significance rs368779259 GRCh38 Chromosome X, 48700340: 48700340
17 TASOR NM_001112736.1(TASOR): c.97G> A (p.Glu33Lys) single nucleotide variant Uncertain significance rs1553733337 GRCh37 Chromosome 3, 56716938: 56716938
18 TASOR NM_001112736.1(TASOR): c.97G> A (p.Glu33Lys) single nucleotide variant Uncertain significance rs1553733337 GRCh38 Chromosome 3, 56682910: 56682910
19 POU3F4 NM_000307.4(POU3F4): c.1013C> T (p.Pro338Leu) single nucleotide variant Uncertain significance rs1555984638 GRCh37 Chromosome X, 82764345: 82764345
20 POU3F4 NM_000307.4(POU3F4): c.1013C> T (p.Pro338Leu) single nucleotide variant Uncertain significance rs1555984638 GRCh38 Chromosome X, 83509337: 83509337
21 PATZ1 NM_032050.1(PATZ1): c.562G> T (p.Asp188Tyr) single nucleotide variant Uncertain significance rs1555894069 GRCh37 Chromosome 22, 31741027: 31741027
22 PATZ1 NM_032050.1(PATZ1): c.562G> T (p.Asp188Tyr) single nucleotide variant Uncertain significance rs1555894069 GRCh38 Chromosome 22, 31345041: 31345041
23 KAT6B NM_012330.3(KAT6B): c.3827C> T (p.Pro1276Leu) single nucleotide variant Uncertain significance rs1554845417 GRCh37 Chromosome 10, 76788409: 76788409
24 KAT6B NM_012330.3(KAT6B): c.3827C> T (p.Pro1276Leu) single nucleotide variant Uncertain significance rs1554845417 GRCh38 Chromosome 10, 75028651: 75028651
25 KREMEN2 NM_172229.2(KREMEN2): c.494G> T (p.Gly165Val) single nucleotide variant Uncertain significance rs1210829529 GRCh37 Chromosome 16, 3016650: 3016650
26 KREMEN2 NM_172229.2(KREMEN2): c.494G> T (p.Gly165Val) single nucleotide variant Uncertain significance rs1210829529 GRCh38 Chromosome 16, 2966649: 2966649
27 DEPDC5 NM_001242897.1(DEPDC5): c.2705G> A (p.Trp902Ter) single nucleotide variant Uncertain significance rs1555900957 GRCh37 Chromosome 22, 32241141: 32241141
28 DEPDC5 NM_001242897.1(DEPDC5): c.2705G> A (p.Trp902Ter) single nucleotide variant Uncertain significance rs1555900957 GRCh38 Chromosome 22, 31845155: 31845155
29 NET1 NM_001047160.2(NET1): c.498G> T (p.Glu166Asp) single nucleotide variant Uncertain significance rs1554818513 GRCh37 Chromosome 10, 5494455: 5494455
30 NET1 NM_001047160.2(NET1): c.498G> T (p.Glu166Asp) single nucleotide variant Uncertain significance rs1554818513 GRCh38 Chromosome 10, 5452492: 5452492
31 SPRY3 NM_005840.2(SPRY3): c.55C> T (p.Arg19Cys) single nucleotide variant Uncertain significance rs779201129 GRCh37 Chromosome X, 155003588: 155003588
32 SPRY3 NM_005840.2(SPRY3): c.55C> T (p.Arg19Cys) single nucleotide variant Uncertain significance rs779201129 GRCh38 Chromosome X, 155773926: 155773926
33 SPRY3 NM_005840.2(SPRY3): c.55C> T (p.Arg19Cys) single nucleotide variant Uncertain significance rs779201129 GRCh38 Chromosome Y, 56960446: 56960446
34 VBP1 NM_003372.6(VBP1): c.331C> A (p.Leu111Met) single nucleotide variant Uncertain significance rs1000821034 GRCh37 Chromosome X, 154456711: 154456711
35 VBP1 NM_003372.6(VBP1): c.331C> A (p.Leu111Met) single nucleotide variant Uncertain significance rs1000821034 GRCh38 Chromosome X, 155228429: 155228429
36 ARHGAP32 NM_001142685.1(ARHGAP32): c.4703C> G (p.Thr1568Ser) single nucleotide variant Uncertain significance rs749174548 GRCh37 Chromosome 11, 128840363: 128840363
37 ARHGAP32 NM_001142685.1(ARHGAP32): c.4703C> G (p.Thr1568Ser) single nucleotide variant Uncertain significance rs749174548 GRCh38 Chromosome 11, 128970468: 128970468
38 OTUD5 NM_017602.3(OTUD5): c.1702C> A (p.Pro568Thr) single nucleotide variant Uncertain significance rs1295653938 GRCh37 Chromosome X, 48780465: 48780465
39 OTUD5 NM_017602.3(OTUD5): c.1702C> A (p.Pro568Thr) single nucleotide variant Uncertain significance rs1295653938 GRCh38 Chromosome X, 48923188: 48923188
40 KLHL21 NM_001324309.1(KLHL21): c.501G> C (p.Glu167Asp) single nucleotide variant Uncertain significance rs1292721663 GRCh37 Chromosome 1, 6662377: 6662377
41 KLHL21 NM_001324309.1(KLHL21): c.501G> C (p.Glu167Asp) single nucleotide variant Uncertain significance rs1292721663 GRCh38 Chromosome 1, 6602317: 6602317
42 NF2 NM_000268.3(NF2): c.551G> A (p.Trp184Ter) single nucleotide variant Likely pathogenic rs1555993293 GRCh37 Chromosome 22, 30051617: 30051617
43 NF2 NM_000268.3(NF2): c.551G> A (p.Trp184Ter) single nucleotide variant Likely pathogenic rs1555993293 GRCh38 Chromosome 22, 29655628: 29655628
44 LATS1 NM_001350339.1(LATS1): c.2050G> C (p.Asp684His) single nucleotide variant Uncertain significance rs750318192 GRCh37 Chromosome 6, 150001239: 150001239
45 LATS1 NM_001350339.1(LATS1): c.2050G> C (p.Asp684His) single nucleotide variant Uncertain significance rs750318192 GRCh38 Chromosome 6, 149680103: 149680103
46 MAP4K3 NM_003618.3(MAP4K3): c.899T> C (p.Phe300Ser) single nucleotide variant Uncertain significance rs1268580645 GRCh37 Chromosome 2, 39552678: 39552678
47 MAP4K3 NM_003618.3(MAP4K3): c.899T> C (p.Phe300Ser) single nucleotide variant Uncertain significance rs1268580645 GRCh38 Chromosome 2, 39325537: 39325537
48 TRAF3 NM_145725.2(TRAF3): c.53C> G (p.Pro18Arg) single nucleotide variant Uncertain significance rs145456077 GRCh37 Chromosome 14, 103336591: 103336591
49 TRAF3 NM_145725.2(TRAF3): c.53C> G (p.Pro18Arg) single nucleotide variant Uncertain significance rs145456077 GRCh38 Chromosome 14, 102870254: 102870254
50 LETM1 NM_012318.2(LETM1): c.286G> A (p.Val96Met) single nucleotide variant Uncertain significance rs753905629 GRCh37 Chromosome 4, 1843382: 1843382

Cosmic variations for Ependymoma:

9 (show all 14)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5977674 RANBP2 central nervous system,spinal cord,glioma,anaplastic c.5736T>G p.S1912R 2:108766275-108766275 0
2 COSM23159 MEN1 central nervous system,fourth ventricle,glioma,ependymoma Grade III-IV c.1413G>A p.W471* 11:64804754-64804754 0
3 COSM150426 KMT2C central nervous system,spinal cord,glioma,anaplastic c.2963G>T p.C988F 7:152229936-152229936 0
4 COSM1179671 KMT2C central nervous system,spinal cord,glioma,anaplastic c.925C>T p.P309S 7:152273792-152273792 0
5 COSM253767 KMT2C central nervous system,spinal cord,glioma,anaplastic c.2959T>C p.Y987H 7:152229940-152229940 0
6 COSM227271 HSP90AB1 central nervous system,spinal cord,glioma,anaplastic c.2156G>A p.R719H 6:44253579-44253579 0
7 COSM327928 H3F3A central nervous system,spinal cord,glioma,anaplastic c.83A>T p.K28M 1:226064434-226064434 0
8 COSM3164376 GATA4 central nervous system,spinal cord,glioma,anaplastic c.1273G>A p.D425N 8:11758419-11758419 0
9 COSM5977673 ALOX12B central nervous system,spinal cord,glioma,anaplastic c.53C>T p.T18I 17:8087390-8087390 0
10 COSM4593267 central nervous system,spinal cord,glioma,anaplastic c.32C>T p.A11V 18:55403683-55403683 0
11 COSM150427 central nervous system,spinal cord,glioma,anaplastic c.2963G>T p.C988F 7:152229936-152229936 0
12 COSM253768 central nervous system,spinal cord,glioma,anaplastic c.2959T>C p.Y987H 7:152229940-152229940 0
13 COSM1179670 central nervous system,spinal cord,glioma,anaplastic c.925C>T p.P309S 7:152273792-152273792 0
14 COSM5977672 central nervous system,spinal cord,glioma,anaplastic c.53C>T p.T18I 17:8087390-8087390 0

Copy number variations for Ependymoma from CNVD:

7 (show top 50) (show all 1024)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13823 1 1 7200000 Deletion Ependymoma
2 15495 1 116080654 116108285 Amplification NHLH2 Ependymoma
3 15648 1 117745152 117779348 Deletion MAN1A2 Ependymoma
4 19381 1 150034000 245120000 Amplification Ependymoma
5 19382 1 150034000 245120000 Amplification Ependymoma
6 26308 1 198898833 198920273 Amplification LGR6 Ependymoma
7 31595 1 2869431 2902617 Amplification TLR5 Ependymoma
8 31803 1 3118000 5001000 Deletion Ependymoma
9 38299 10 101279725 101300855 Deletion NKX2 Ependymoma
10 38453 10 102724768 102752246 Deletion LZTS2 Ependymoma
11 38454 10 102724768 102752246 Deletion MRPL43 Ependymoma
12 38455 10 102724768 102752246 Deletion PEO1 Ependymoma
13 38456 10 102724768 102752246 Deletion SEMA4G Ependymoma
14 38866 10 105634726 105742493 Deletion OBFC1 Ependymoma
15 38867 10 105634726 105742493 Deletion SLK Ependymoma
16 38979 10 106855945 106907237 Deletion SORCS3 Ependymoma
17 39169 10 11151805 11236375 Deletion CUGBP2 Ependymoma
18 40763 10 13344307 13497936 Deletion PHYH Ependymoma
19 40764 10 13344307 13497936 Deletion SEPHS1 Ependymoma
20 40806 10 133827559 133847021 Amplification C10orf39 Ependymoma
21 40809 10 133852261 133910912 Deletion DPYSL4 Ependymoma
22 40810 10 133852261 133910912 Deletion STK32C Ependymoma
23 40887 10 134410586 134892955 Deletion C10orf92 Ependymoma
24 40888 10 134410586 134892955 Deletion C10orf93 Ependymoma
25 40889 10 134410586 134892955 Deletion GPR123 Ependymoma
26 40890 10 134410586 134892955 Deletion INPP5A Ependymoma
27 40891 10 134410586 134892955 Deletion KNDC1 Ependymoma
28 40892 10 134410586 134892955 Deletion NKX6 Ependymoma
29 41033 10 135073302 135095235 Amplification ECHS1 Ependymoma
30 41034 10 135073302 135095235 Amplification PAOX Ependymoma
31 41074 10 135176625 135276748 Deletion CYP2E1 Ependymoma
32 41075 10 135176625 135276748 Deletion FLJ44653 Ependymoma
33 41076 10 135176625 135276748 Deletion SYCE1 Ependymoma
34 41910 10 25665327 25756077 Deletion GPR158 Ependymoma
35 42307 10 3169189 3180797 Deletion PITRM1 Ependymoma
36 44077 10 5175582 5187881 Deletion AKR1CL1 Ependymoma
37 44224 10 53651276 53712562 Deletion PRKG1 Ependymoma
38 44704 10 6170011 6268419 Deletion RBM17 Ependymoma
39 45199 10 68970214 69114993 Deletion CTNNA3 Ependymoma
40 45273 10 69645873 69701073 Deletion ATOH7 Ependymoma
41 45408 10 70846341 70896472 Deletion TSPAN15 Ependymoma
42 45468 10 71234506 71351772 Deletion COL13A1 Ependymoma
43 45538 10 71990162 72295747 Deletion ADAMTS14 Ependymoma
44 45539 10 71990162 72295747 Deletion C10orf27 Ependymoma
45 45540 10 71990162 72295747 Deletion KIAA1274 Ependymoma
46 45541 10 71990162 72295747 Deletion PRF1 Ependymoma
47 45542 10 71990162 72295747 Deletion SGPL1 Ependymoma
48 45578 10 72636128 72774965 Deletion SLC29A3 Ependymoma
49 45579 10 72636128 72774965 Deletion UNC5B Ependymoma
50 45628 10 73121579 73231404 Deletion C10orf54 Ependymoma

Expression for Ependymoma

Search GEO for disease gene expression data for Ependymoma.

Pathways for Ependymoma

GO Terms for Ependymoma

Biological processes related to Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.65 NCAM1 RB1 RELA TP73 VIM
2 Bergmann glial cell differentiation GO:0060020 9.16 GFAP VIM
3 response to cobalamin GO:0033590 8.96 EGFR RELA
4 intermediate filament-based process GO:0045103 8.62 GFAP VIM

Molecular functions related to Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.28 EGFR GFAP RB1 RELA S100B SYP

Sources for Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....